Related Stocks:
Leading Stocks (600630)
And Related Reasons: Shanghai Shuanglong Hi-Tech Development Co. Ltd, the holding company of Shanghai SASAC, owns modern textile manufacturing bases, in which the company has a 94% stake, and is mainly engaged in the development of bioproducts and scientific and technological new materials.
Main business: brand sales and ethnic trade, apparel and home textiles
Theme: new retail Ebola concept of local state-owned reform
Company profile: Shanghai Dragon Head (Group) Co. Ltd. is mainly engaged in brand sales and international trade. Its main products include knitted underwear, home series, leisure series, underwear, bra, bed sheet, quilt cover, pillowcase, back cover, quilt, blanket, towel, shirt, casual pants, t-shirt, sweater, jacket, down jacket, coat and so on.
Shuanglu Pharmaceuticals (002038)
And the reason for inclusion: a leading position in the treatment of tumors, liver and kidney diseases, diabetes, cardiovascular and cerebral vascular diseases, the company is China's backbone of the genetic engineering drug industry.
Main business: research, development, production and operation of genetic engineering and related drugs.
Theme concept: biomedical gene sequencing heparin
Company profile: R & D; R & D and production of the P management, Jinduo regiment support soldiers No layout changes, R & D; R & D and production of the main products include Beijing Shuanglu Pharmaceuticals Co., Ltd., mainly to genetic engineering and related drugs, such as recombinant human basic fibroblast growth factor, temozolomide, arsenic trioxide, lainadu Amine, Compound Adjuvant Recombinant Human Granulocyte Stimulating Factor, Recombinant Human Interleukin 2, Recombinant Human Interleukin 11 Docetaxel, Adefovir Apricot Drops and so on. Associated with tumors, liver disease, and cardiovascular disease. Enzyme, thymus peptide, root Huafang Kai sodium, aminotetracycline dispersible tablets, the first batch of "100 innovative enterprises" in Ximixiang Park, Beijing Biomedical Industry Leapfrog Development Project (G20 Project), Zhongguancun National Race Zone selected as the key high-tech enterprises of the National Torch Plan, the first batch of the Haidian Pharmaceutical Innovation Demonstration Zone of the Zhongguancun Science and Technology Park. "100,000 project key cultivation enterprises".
Qian Da Pharmacy (002550)
And the reason for selection: the domestic biochemical pharmaceutical industry well-known polysaccharide and protease production enterprise Jinghongsheng branch of the new crown of pneumonia nucleic acid detection kit to obtain CE certification.
Main business: research and development; d, drug production license within the scope of lyophilized powder, lyophilized powder injection (including anti-tumor drugs), small volume injection (non-final sterilization), tablets, hard capsules, granules, the production and sale of APIs.
Theme Concept: Consistency Evaluation of Generic Biomedical Heparin
Company Profile: Changzhou Hongqian Biochemical Pharmaceutical Co., Ltd. is mainly engaged in the research and development, production and sales of lyophilized powder, lyophilized powder injection (including anti-tumor drugs), small volume injection (non-final sterilizable), tablets, hard capsules, granules, and raw materials within the scope of the drug production license. The company has 46 product specifications, including tablets, hard capsules, lyophilized powder and lyophilized powder injections, small volume injections and APIs. The main products include two series of biochemical drugs, active enzymes and polysaccharides. Among them, the active enzymes mainly include pancreatic kininogenase series, compound digestive enzyme capsules, elastase and 1-donamidase series; polysaccharide varieties mainly include sodium heparin and low molecular weight heparin series varieties. As an expert in the field of enzyme preparations of animal origin, the main variety of Yikai brand is honored as a national well-known trademark.
Huarun Sanjiu (000999)
And the reason for inclusion: OTC companies ranked first in the overall ranking, with a well-known pharmaceutical brand '999'. The company's main products include: 999 cold and flu spirit, cephalosporin for injection and so on.
Main business: research and development; d, production and sales of pharmaceutical products and related health services.
Theme concept: influenza Chinese medicine central enterprise state-owned reform
Company profile: China Resources Sanjiu Pharmaceutical Co., Ltd. is mainly engaged in the research and development of pharmaceutical products, production, sales and related health services. The main products are 999 cold and flu, 999 dermatitis ping, ginseng injection, cephalosporin for injection, free decoction of traditional Chinese medicine, Sanjiu gastrointestinal particles, Zhengtian pill and so on. The main brand of "999" en
And the reason for selection: realized the localization of microbial detection and control technology, and became the leading enterprise in the industry. The company produces microbial detection technology series and other products in the field of microbiology-related drug quality inspection has an important value.
Main business: research and development; d, microbial detection and control technology system products and organic analytical instruments and other pharmaceutical equipment manufacturing and sales.
Theme concept: the new crown pneumonia food safety and biosafety testing
Company profile: zhejiang tailin biological science and technology co., ltd main business for microbial detection and control technology system products and organic analytical instruments, such as pharmaceutical equipment, research and development, manufacturing and sales. The company's main products are microbial detection technology series, separation technology series and sterilization technology series of various consumables, instruments and equipment. The company was awarded the "First Prize of Advanced Collective for Technological Innovation in China Pharmaceutical Equipment Industry" by China Pharmaceutical Equipment Industry Association.
Wanfo Bio(300482)
Reason for selection: excellent supplier of rapid test products in the in vitro diagnostic industry, and the company's colloidal gold antibody test reagents won the bidding for the Beijing-Tianjin-Hebei joint procurement.
Main business: research and development; rapid diagnostic reagents and supporting instruments manufacturing, sales and service.
Theme concept: biomedical gene sequencing hepatitis concept
Company profile: Guangzhou Wanzi Biotechnology Co., Ltd. specializes in rapid diagnostic reagents and ancillary instrumentation research and development, manufacturing, marketing and service, is one of China's leading POCT enterprises. Product lines in major testing areas such as cardiovascular, inflammation, tumor, infectious disease, drug testing (drug abuse), eugenics, etc. In 2019, the company was awarded the MDSAP certificate for the first time, which proves that the company's quality system complies with the IS013485:2016 standard and the regulatory requirements of FDA, HC, TGA in Australia and ANMISA in Brazil.
Huarun Crane (600062)
And the reason for the selection: the largest infusion supply base in China, and the nation's leading production base of fully synthetic antimicrobial drugs. The company has a long time ago the production number of Ebola inhibitor drugs, also produces raw materials.
Elected by the State Food and Drug Administration to designate the fixed production of Ebola inhibitors indicator is more likely
Main business: chronic disease business, specialty business and infusion business three major businesses.
Theme concept: artemisinin influenza heparin centralized state-owned enterprises reform
Company profile: Huama Hanfei Pharmaceutical Company Limited is the main business for the three major businesses of chronic disease business, specialty business and field flush business. The main products include compound lihexepin aminophyllotoxin tablets No. 0) cytosine sulfur biliary albumin sodium tablets Xibai Note), fortunately vehicle acid amlodipine tablets low Thida) C nine super pendulum slow course tablets Hi Sue), Geli Zhongqiang Chao tablets储适平)Soft bag (including straight soft, internal sealing polypropylenic end infusion.
Ten people who speculate in the stock market, nine do not know how to "choose the bone, timing, wind control," which is the root cause of the speculation of the bone lost money.
Lao Xiao solemn commitment: friendly exchange! Welcome good character, high quality, love to learn the stockholders to discuss with each other!
(1) learn to look at the general market trend, select the strong plate
(2) learn to distinguish between the short-term ticket of the main lobbyist, and the trend of the main institutional ticket
(3) learn to eat meat with the main force - up, and the main force *** in and out of the
(4) learn to take profit and stop-loss and position management, say goodbye to the heavy losses
(5) learn to develop a trading plan, the implementation of the trading plan, summarize the experience of insights
(6)Every day to share the general market trends, plate evolution and capture the logic of the bull, do the most valuable content.
Pick the strongest stocks, do the top masters, with you!
Every day before the plate 9:30, punctually updated exclusive articles and collection of bidding stocks, after the close of the market from time to time to update the exclusive review article!
Additionally mention that there was a lot of negative news over the weekend, so much so that market sentiment was generally pessimistic. And the more in this case, the more we have to remain sober and calm, and frankly face. At the moment, it is not appropriate to continue to say those negative and pessimistic statements, because it will only increase anxiety and will not help.
This week, the most important thing may still be to control the position, do not be too reckless, full position remember to squeeze some space out. This period of time foreign sudden outbreak of unknown hepatitis attacks on children, make people panic, so the concept of hepatitis has the opportunity to become the capital of the speculation point, you can take a look at.
And the recent new shares frequently broke, so that the enthusiasm of the shareholders to play the new sharply reduced, a serious setback in confidence. In order to "old folks don't go", this week's new stocks and sub-new stocks may put on a good show, you can watch the show. And then there is agriculture, the people to food, expected to have, and just after the adjustment, not to be abandoned.
In fact, some movements from the weekend can also be seen, the market at the moment _ situation above is actually very nervous; of course, the point of tension may not be the same as us. However, when the emotions are excessive venting, I believe that they can not completely ignore, after all, the impact is not good.
All in all, be careful, the most important thing is still defense before the May Day holiday, after all, if this week is not a good week will also affect the May Day holiday mood.
Related Q&A: leading pharmaceutical stocks for the treatment of liver diseaseStock: Frui shares.
Furui shares (300049): leading liver disease. This company has a liver disease whole industry chain medical service platform, the main diagnostic products for the Fibroscan series of liver fibrosis diagnostic instrument, is the world's first non-invasive liver fibrosis detection equipment; hold 13.01% of the equity of France Median, which is a high-end tumor imaging software provider; 17 years of medical equipment revenue of 494 million, accounting for 58.09%.
The company's main business is drug production and sales, diagnostic equipment development and sales, and O2O heavy vertical chronic liver disease management medical service business.
Characteristics of Fortune:
The company is a pharmaceutical manufacturer and medical service provider focusing on the field of liver disease, and its main business is divided into three areas: pharmaceutical production and sales of Compound Tetramethylene Liver Tablet as the leading product; production and sales of the world's exclusive and innovative Fibroscan series of medical devices, which is an innovative and quantitative test for liver hardness and steatosis. "Fibroscan, the world's only innovative quantitative test for liver hardness and steatosis; and the production and sale of medical devices; we are building a vertically integrated chronic liver disease management platform, providing related medical services and selling related medicines as an agent.